Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311830 | PMC |
| http://dx.doi.org/10.1016/j.xjtc.2021.02.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nonnegligible cascading impacts of global urban expansion on net primary productivity.
PNAS Nexus
January 2025
Key Laboratory of Geographic Information Science (Ministry of Education), School of Geographic Sciences, East China Normal University, Shanghai 200241, China.
Accelerated global urban expansion not only directly occupies surrounding ecosystems, but also induces cascading losses of natural vegetation elsewhere through cropland displacement. Yet, how such effects alter the net primary productivity (NPP) worldwide remains unclear. Here, we quantified the direct and cascading impacts of global urban expansion on terrestrial NPP from 1992 to 2020 and projected the impacts under the shared socioeconomic pathways framework by 2100.
View Article and Find Full Text PDFA review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole.
Curr Med Res Opin
January 2025
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a long-acting injectable antipsychotic that was approved for use in Europe in March 2024, for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole; it is administered via gluteal intramuscular injection once every two months. This review examines population pharmacokinetic model-based simulations relevant to the use of Ari 2MRTU in Europe, accompanied by expert commentary that contextualizes the simulations and highlights the potential implications of the availability of Ari 2MRTU for patients, caregivers, and clinicians. Various simulations conducted across 8 weeks (representing the first dosing interval), or 32 weeks (representing maintenance dosing) demonstrated an aripiprazole exposure profile for Ari 2MRTU that was similar to aripiprazole once-monthly (AOM), but with an extended dosing interval.
View Article and Find Full Text PDFImproving eating disorder care for underserved groups: a lived experience and quality improvement perspective.
J Eat Disord
January 2025
, London, UK.
Improvements to eating disorder (ED) care are urgently needed in the United Kingdom (UK) and around the world. Informed by my lived experiences, independent research, and involvement in the underappreciated field of quality improvement (QI), I have written this article to offer ideas on how to improve individuals' access to and experiences of ED care. As I live in the UK, my lived and QI experiences are of the UK's National Health Service (NHS).
View Article and Find Full Text PDFBeyond Longer Intervals: Advocating for Regular Treatment of Neovascular AMD.
J Clin Med
December 2024
Division of Ophthalmology, Department of Surgery, UMass Chan-Lahey School of Medicine, Burlington, MA 01805, USA.
Personalizing the management of neovascular age-related macular degeneration (nAMD) poses significant challenges for practicing retina specialists and their patients. This commentary addresses some of these complexities, particularly those that arise in the context of an expanding array of intravitreal agents targeting vascular endothelial growth factor (VEGF) and related retinal disease targets. Many of these newer agents approved by the Food and Drug Administration (FDA) for the treatment of nAMD have labeling that indicates that they can provide non-inferior visual outcomes when compared head-to-head with previously available treatments and can be used at significantly extended dosing intervals in some patients.
View Article and Find Full Text PDFDevelopments and future directions in neurodevelopmental research: A commentary on 'camouflaging in neurodivergent and neurotypical girls at the transition to adolescence and its relationship to mental health: A participatory methods research study'.
JCPP Adv
December 2024
Autism Centre for Education and Research (ACER) Department of Disability, Inclusion and Special Needs (DISN) School of Education University of Birmingham Birmingham UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!